title: A randomized trial to measure the optimal role of the pharmacist in promoting evidence-based antibiotic use in acute care hospitals.
abstract: BACKGROUND
  There is a considerable gap between randomized clinical trials and implementing the results into practice. This is particularly relevant in the use of broad-spectrum antibiotics in hospitals. Hospital pharmacists can be effective vehicles for bridging this gap and promoting evidence-based medicine. To determine the most effective way of using the pharmacist in this role, a prospective cefotaxime intervention study was conducted with randomization incorporated into the design as well as patient-related therapeutic outcomes.
  
  
  METHODS
  A total of 323 patients who were prescribed cefotaxime were randomized into an intervention or nonintervention group where only the former was challenged by pharmacists for inappropriate cefotaxime usage relative to hospital guidelines. The primary outcome was the appropriateness of cefotaxime prescribing between groups. Logistic regression analysis was then used to identify factors that were associated with successful clinical response.
  
  
  RESULTS
  Overall, 94% of orders in the intervention group met cefotaxime dosage criteria compared with 86% in the control group (p = .018). However, there was no impact with respect to promoting cefotaxime use for an appropriate indication (81% vs. 80%; p = .67). There was a trend for improved clinical outcomes in patients who received cefotaxime within hospital guidelines (OR = 1.73; p = .31).
  
  
  CONCLUSIONS
  The pharmacist as a vehicle for promoting the appropriate use of broad-spectrum antibiotics in the acute care hospital setting can improve the dosing of such agents. However, several barriers to optimizing the impact of the pharmacist were implied by the data. Removing these barriers could increase the pharmacists' utility as an agent for improved patient care.
authors.affiliation: Mt. Sinai Hospital.
authors.forename: G
authors.initials: G
authors.lastname: Dranitsaris
authors.forename: D
authors.initials: D
authors.lastname: Spizzirri
authors.forename: M
authors.initials: M
authors.lastname: Pitre
authors.forename: A
authors.initials: A
authors.lastname: McGeer
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002439:Cefotaxime / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D017723:Drug Utilization Review; D019317:Evidence-Based Medicine; D006786:Hospitals, Urban / Q000458:organization & administration*; D006801:Humans; D009864:Ontario; D017063:Outcome Assessment, Health Care; D010595:Pharmacists; D010607:Pharmacy Service, Hospital; D011446:Prospective Studies
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002439:Cefotaxime